- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06072001
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis
January 30, 2024 updated by: Apurano Pharmaceuticals GmbH
Over the last years a rising medical need for treatment of chronic pain was identified.
Based on previous findings indicating the pain modulating effects of cannabinoids in chronic pain disorders, this clinical trial investigates the long term efficacy and tolerability of the THC-focused nano endocannabinoid system modulator AP707 in patients with chronic pain disorders due to central neuropathy of any genesis.
Patients receive AP707 or placebo over the course of 14 weeks as an add-on to the standard of care.
Changes in pain intensity, quality of life and sleep and others measures are monitored through different scales to assess the efficacy of AP707 in patients with chronic pain due to central neuropathy of any genesis.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
558
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Marko Blisse
- Phone Number: +49 8024 46869 28
- Email: marko.blisse@apurano.de
Study Locations
-
-
Bavaria
-
Munich, Bavaria, Germany, 81675
- Recruiting
- Klinikum Rechts der Isar (Zentrum für Interdisziplinäre Schmerztherapie)
-
Contact:
- Katharina Haas
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Signed and dated informed consent form
- Patients with chronic pain due to central neuropathy of any genesis since at least 3 months
- Female and male patients (> 18 years)
- Patients with more than 1 year life expectancy
- Patients with optimized sCPT on study entry as defined in section 3.1.1 and section 3.1.3 of the study protocol
- Willingness of study patients of both sexes to use reliable contraception during study participation and for three months after taking the last study medication
- Good command of German language, in order to understand questionnaires in German
- Current moderate to severe pain with pain intensity > 5 on Numeric Rating Scale (NRS, 0 - 10) and thus an existing need for further pain therapy
- Completed QUISS (Quantification Inventory for Somatoform Syndromes) questionnaire with 45 or less score points
Exclusion Criteria:
- Medical history of hypersensitivity or intolerance to the investigational product or its ingredients or to ingredients of similar chemical structure
- Known intolerance to cannabinoids or cannabis products.
- Participation in another clinical trial within the last four weeks prior to inclusion.
- Pregnant or nursing women (as excluded by pregnancy testing at visit 1).
- Other medical conditions that do not allow the trial subject to appraise the nature, scope, and potential consequences of the clinical trial
- Indications that the trial subject is unlikely to comply with the study protocol (e.g., unwillingness to cooperate)
- Known use of medicinal cannabis products within the last 8 weeks
- Active malignant tumor disease, tumor pain, or other dominant severe pain other than that of the study indication
- Known history of severe liver or kidney diseases
- Known history of severe cardiovascular disease
- Known history of or acute mental illness such as severe depression, psychosis, bipolar disorder, mania, anxiety, or obsessive-compulsive disorder
- Known history of addictive disease (e.g., alcohol, medication, drug addiction)
- Answered during Screening less than 12 times of 18 the pain intensity (NRS) inquiry
- Laboratory liver values: Alanine aminotransferase (ALT, GPT) > 3 x ULN (Upper Limit of Normal range), Aspartate aminotransferase (AST, GOT) > 3 x ULN, Alkaline phosphatase (AP) > 2.5 x ULN, and for bilirubin > 1.5 x ULN
- Laboratory renal value: Serum creatinine > 1.5 ULN
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment group
Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
|
Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
|
Experimental: Control group
Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
|
Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in pain level on the Numeric Rating Scale (NRS, 0-10) between baseline and at treatment week 14 (end of first treatment phase) in comparison of study arm 1 (verum) and study arm 2 (placebo)
Time Frame: Once daily in week 4 and 14
|
Once daily in week 4 and 14
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in pain level on the Numeric Rating Scale (NRS, 0-10) between baseline and at treatment week 26 (end of second treatment phase) in comparison of study arm 1 (verum) and study arm 2 (placebo)
Time Frame: Once daily in week 4 and 26
|
Once daily in week 4 and 26
|
|
Change in pain level on the Numeric Rating Scale (NRS, 0-10) between baseline and at treatment week 52 (end of third treatment phase) in comparison of study arm 1 (verum) and study arm 2 (placebo)
Time Frame: Once daily in week 4 and 52
|
Once daily in week 4 and 52
|
|
Change in the pain score of the Neuropathic Pain Symptom Inventory (NPSI) questionnaire between baseline and at treatment week 14, treatment week 26 and treatment week 52 in comparison of study arm 1 (verum) and study arm 2 (placebo)
Time Frame: Once in week 1, 14, 26 and 52
|
Once in week 1, 14, 26 and 52
|
|
Change in pain level on the Numeric Rating Scale (0-10) between baseline and in treatment week 5, 11, 18, 22, 30, 34, 43, 47 in comparison of study arm 1 (verum) and study arm 2 (placebo)
Time Frame: Several times weekly in week 4, 5, 11, 18, 22, 30, 34, 43 and 47
|
Several times weekly in week 4, 5, 11, 18, 22, 30, 34, 43 and 47
|
|
Responder analysis for endpoints 1), 2), 3) and 4) for treatment week 14, 26 and 52
Time Frame: Week 14, 26 and 52
|
|
Week 14, 26 and 52
|
Change in sCPT (percentage of change in dosage and percentage of change in combination of analgesic measures) in both study arms from start to week 14
Time Frame: Week 14
|
Week 14
|
|
Change in psychological distress using Depression Anxiety Stress Scales Short Form (DASS-21) questionnaire from start to week 14, 26, and 52
Time Frame: Week 1, 14, 26 and 52
|
Week 1, 14, 26 and 52
|
|
Change of Patient Global Impression of Change (PGIC) from start to week 14, 26, and 52
Time Frame: Week 14, 26 and 52
|
Week 14, 26 and 52
|
|
Change in quality of life using the Veterans RAND (VR-12) questionnaire from start to week 14, 26, and 52
Time Frame: Week 1, 14, 26 and 52
|
Week 1, 14, 26 and 52
|
|
Change in sleep quality using the Regensburg Insomnia Scale (RIS) from start to week 14, 26, and 52
Time Frame: Week 1, 14, 26 and 52
|
Week 1, 14, 26 and 52
|
|
Change in pain score of the Brief Pain Inventory - Short Form (BPI-SF) questionnaire from start to week 14, 26, and 52
Time Frame: Week 1, 14, 26 and 52
|
Week 1, 14, 26 and 52
|
|
Area under NRS-curve until treatment week 5, 11, 14, 18, 22, 26, 30, 34, 39, 43, 47, 52
Time Frame: Week 5, 12, 18, 22, 26, 30, 34, 39, 43, 47 and 52
|
Week 5, 12, 18, 22, 26, 30, 34, 39, 43, 47 and 52
|
|
Change in VR-12 components (physical component summary PCS, mental component summary MCS) from start to week 14, 26, and 52
Time Frame: Week 1, 14, 26 and 52
|
Week 1, 14, 26 and 52
|
|
Number of patients with rescue medication over the course of the clinical trial and within periods: until treatment week ≤5, ≤11, ≤14, ≤18, ≤22, ≤26, ≤30, ≤34, ≤43, ≤47, ≤52
Time Frame: Week 5, 11, 14, 18, 22, 26, 30, 34, 43, 47 and 52
|
Week 5, 11, 14, 18, 22, 26, 30, 34, 43, 47 and 52
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number and severity of adverse events (AE)
Time Frame: Week 1 to 52
|
Week 1 to 52
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 2, 2023
Primary Completion (Estimated)
September 30, 2024
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
September 25, 2023
First Submitted That Met QC Criteria
October 5, 2023
First Posted (Actual)
October 10, 2023
Study Record Updates
Last Update Posted (Actual)
January 31, 2024
Last Update Submitted That Met QC Criteria
January 30, 2024
Last Verified
September 1, 2023
More Information
Terms related to this study
Keywords
- Multiple Sclerosis
- Stroke
- Pain
- Chronic Pain
- Cannabis
- THC
- Central Nervous System
- Traumatic Brain Injury
- CNS
- Phantom Pain
- Neuropathic Pain
- Central Neuropathic Pain
- Paraplegia
- Tetrahydrocannabinol
- Cannabinoids
- Pain Syndrome
- Pain Therapy
- Chronic Pain Syndrome
- Adezunap
- Delta-9-Tetrahydrocannabinol
- Phantom Limb Syndrome with Pain
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Postoperative Complications
- Pain
- Neurologic Manifestations
- Wounds and Injuries
- Neurobehavioral Manifestations
- Disease
- Neuromuscular Diseases
- Peripheral Nervous System Diseases
- Craniocerebral Trauma
- Trauma, Nervous System
- Paralysis
- Perceptual Disorders
- Pain, Postoperative
- Multiple Sclerosis
- Sclerosis
- Syndrome
- Chronic Pain
- Brain Injuries
- Neuralgia
- Brain Injuries, Traumatic
- Somatoform Disorders
- Phantom Limb
- Paraplegia
Other Study ID Numbers
- DISCOVER__(ZNP)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.RecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, CryptogenicSingapore, Philippines
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Vanderbilt University Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at BirminghamEnrolling by invitationStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Engagement, Patient | Stroke HemorrhagicUnited States
-
University of MinnesotaAmerican Occupational Therapy FoundationRecruitingStroke | Stroke Sequelae | Stroke Hemorrhagic | Stroke IschemicUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
University of CincinnatiMedical University of South Carolina; University of California, Los Angeles; University...RecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke HemorrhagicUnited States
-
University of LiegeCompletedStroke, Acute | Stroke Hemorrhagic | Stroke, ComplicationBelgium
-
Turkish Stroke Research and Clinical Trials NetworkElectroCore INC; Turkish Neurological SocietyCompletedStroke | Stroke, Ischemic | Stroke, Acute | Stroke, HemorrhagicTurkey
Clinical Trials on Adezunap (AP707)
-
Apurano Pharmaceuticals GmbHRecruitingPain | Lower Back Pain | Back Pain | Chronic Pain | Pain, Chronic | Chronic Pain Syndrome | Pain Syndrome | Lower Back Pain ChronicGermany
-
Apurano Pharmaceuticals GmbHRecruitingPain | Lower Back Pain | Back Pain | Chronic Pain | Pain, Chronic | Chronic Pain Syndrome | Pain Syndrome | Lower Back Pain ChronicGermany
-
Apurano Pharmaceuticals GmbHRecruitingPain | Diabetes | Diabetic Neuropathies | Chronic Pain | Peripheral Neuropathy | Pain, Chronic | Chronic Pain Syndrome | Diabetic Polyneuropathy | Pain Syndrome | Peripheral Neuralgia | Peripheral Neuropathy With Type 2 DiabetisGermany
-
Apurano Pharmaceuticals GmbHRecruitingPain | Chronic Pain | Neuropathic Pain | Peripheral Neuropathy | Pain, Chronic | Post Operative Pain | Chronic Pain Syndrome | Pain Syndrome | Peripheral Nerve Injury | Post-Traumatic Neuralgia | Peripheral Neuralgia | PlexopathyGermany
-
Apurano Pharmaceuticals GmbHRecruitingPain | Diabetes | Diabetic Neuropathies | Chronic Pain | Peripheral Neuropathy | Pain, Chronic | Chronic Pain Syndrome | Diabetic Polyneuropathy | Pain Syndrome | Peripheral Neuralgia | Peripheral Neuropathy With Type 2 DiabetisGermany
-
Apurano Pharmaceuticals GmbHRecruitingPain | Chronic Pain | Neuropathic Pain | Peripheral Neuropathy | Pain, Chronic | Post Operative Pain | Chronic Pain Syndrome | Pain Syndrome | Peripheral Nerve Injury | Post-Traumatic Neuralgia | Peripheral Neuralgia | PlexopathyGermany
-
Apurano Pharmaceuticals GmbHRecruitingStroke | Pain | Multiple Sclerosis | Chronic Pain | Traumatic Brain Injury | Neuropathic Pain | Pain, Chronic | Chronic Pain Syndrome | Paraplegia | Phantom Pain | Pain Syndrome | Central Neuropathic Pain | Phantom Limb Syndrome With PainGermany
-
CannaXan GmbHCompletedPharmacokinetics | Tolerability | SafetyGermany